60 yr old female known SHTN came with dyspnea for 1 day and pedal edema for 1 week

Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Searching PubMed

"heart failure" "hypertension" management guidelines

I now have enough information from the medical library to give a thorough, structured clinical response. Here is the complete clinical approach:

Clinical Approach: 60F with Hypertension, Dyspnea (1 day) + Pedal Edema (1 week)

Provisional Diagnosis

Acute Decompensated Heart Failure (ADHF) - most likely HFpEF (Heart Failure with Preserved Ejection Fraction) secondary to Hypertensive Heart Disease, until proven otherwise.
The combination of:
  • Known systemic hypertension (SHTN) - the single most common cause of HF in women
  • Acute dyspnea (suggests raised LVEDP / pulmonary congestion)
  • Pedal edema for 1 week (suggests systemic venous congestion / right-sided or biventricular failure)
...is a classic presentation of hypertension-driven heart failure.

Differential Diagnoses

#DiagnosisKey Distinguishing Features
1Hypertensive HF (HFpEF)Most likely given long-standing HTN, LVH
2HF with Reduced EF (HFrEF)Dilated cardiomyopathy; EF <40% on echo
3Acute Coronary SyndromeChest pain, dynamic ECG changes, troponin rise
4Pulmonary embolismPleuritic chest pain, tachycardia, D-dimer
5Chronic Kidney Disease with fluid overloadElevated creatinine, uremia symptoms
6Mitral/Aortic valve diseaseMurmur on auscultation, prior rheumatic fever
7Thyroid dysfunction (hypothyroid)Bradycardia, myxedema facies, TSH abnormal
8Severe anemiaPallor, tachycardia, Hb low

History to Elicit

Cardiac/Respiratory:
  • Orthopnea (how many pillows?) and paroxysmal nocturnal dyspnea (PND) - hallmarks of LV failure
  • Exertional dyspnea - NYHA functional class
  • Chest pain or palpitations
  • Prior cardiac history, previous echo findings
Edema Characterization:
  • Onset, progression, symmetry of edema
  • Ascites, right upper quadrant discomfort (hepatomegaly from RV failure)
HTN History:
  • Duration of hypertension, BP control, current antihypertensives
  • Compliance with medications
Risk Factors:
  • Diabetes mellitus, dyslipidemia, CAD, smoking
  • Alcohol use (dilated cardiomyopathy)
  • Thyroid disorders, anemia
Review of Systems:
  • Fever, weight loss (infective/malignant cause)
  • Recent illness, URTI (viral myocarditis trigger)

Physical Examination

Vital Signs

  • BP (both arms - expect elevated), HR, RR, SpO2, temperature

General

  • Respiratory distress, tripod positioning, ability to speak in sentences

Cardiovascular

  • JVP elevation (>3 cm above sternal angle) - key sign of elevated venous pressure
  • Apex beat - displaced laterally/inferiorly (LV dilatation) or sustained/heaving (LVH)
  • S3 gallop - sign of volume overload / systolic dysfunction
  • S4 gallop - sign of diastolic dysfunction (very common in hypertensive HF)
  • Murmurs (aortic stenosis, mitral regurgitation as contributing causes)

Respiratory

  • Bilateral basal crepitations (pulmonary edema)
  • Pleural effusion (dullness at bases, reduced breath sounds)

Abdomen

  • Hepatomegaly, hepatojugular reflux
  • Ascites (in severe RV failure)

Extremities

  • Pitting pedal/ankle edema - grade and extent (ankle, leg, thigh)
  • Peripheral perfusion - warm (high output) vs cold (low output - cardiogenic shock)

Investigations

Immediate / Bedside

TestExpected Finding in HF
ECGLVH (Sokolow-Lyon criteria), strain pattern, AF, ischemic changes
SpO2Reduced (<94%) - severity of pulmonary edema
Capillary blood glucoseRule out hyperglycemic crises

Bloods (Urgent)

TestRationale
BNP / NT-proBNPKey biomarker - elevated in HF; BNP >100 pg/mL or NT-proBNP >300 pg/mL supports diagnosis
CBCAnemia as precipitant or contributor
Renal function (BMP)Baseline creatinine - essential before initiating diuretics/ACEi
Serum electrolytesHyponatremia (poor prognosis), hypokalemia (risk with diuresis)
LFTsHepatic congestion (congestive hepatopathy)
Thyroid function (TSH)Hypothyroidism as cause; hyperthyroidism as precipitant
Troponin I/TRule out ACS as precipitant
HbA1c, fasting lipidsComorbidity assessment
UrinalysisProteinuria (hypertensive nephropathy), casts

Imaging

TestExpected Finding
Chest X-ray (PA)Cardiomegaly (CTR >0.5), upper lobe diversion, Kerley B lines, bilateral perihilar haziness ("bat-wing"), pleural effusions
Echocardiogram (TTE) - KEYLVH, EF assessment (distinguishes HFpEF vs HFrEF), diastolic dysfunction grading (E/A ratio, E/e'), wall motion abnormalities, valve lesions, pericardial effusion

Management

Immediate (Emergency Stabilization)

  1. Position: Sit upright (reduces venous return, eases dyspnea)
  2. Oxygen: Target SpO2 94-98%; consider NIV (BiPAP) if severe respiratory distress / pulmonary edema
  3. IV Access + cardiac monitor + continuous SpO2
  4. IV Furosemide (Loop diuretic - first-line for congestion):
    • 40-80 mg IV stat (if diuretic-naive); double usual oral dose if already on diuretics
    • Onset of action ~30 minutes IV; monitor urine output
  5. BP Control: If severely hypertensive (e.g. SBP >180), use IV nitrates (GTN infusion) - reduces preload and afterload; avoid rapid drops
  6. Morphine: Use cautiously (only if very distressed) - reduces sympathetic drive and anxiety; can cause respiratory depression

Acute Oral / Short-term

Drug ClassAgentIndication
Loop diureticFurosemide 40-80 mg OD/BD PODecongestion - cornerstone
ACE inhibitorEnalapril 2.5 mg BD → titrate to 10-20 mg BDLVSDF, reduces remodeling, mortality benefit
Beta-blockerCarvedilol 3.125 mg BD / Bisoprolol 1.25 mg ODAfter stabilization (avoid in acute decompensation); BP + rate control
MRASpironolactone 25-50 mg ODEF <35%, reduces mortality

Long-term GDMT (Guideline-Directed Medical Therapy) - "Fantastic Four" for HFrEF

Per Goldman-Cecil Medicine:
  1. ACE inhibitor / ARB / ARNI (Sacubitril-Valsartan if tolerates, superior to ACEi alone in HFrEF)
  2. Beta-blocker (Carvedilol, Bisoprolol, or Metoprolol succinate)
  3. MRA (Spironolactone or Eplerenone)
  4. SGLT2 inhibitor (Dapagliflozin or Empagliflozin - reduces HF hospitalization and CV death)
If HFpEF (preserved EF): management is primarily diuretics for symptom relief + aggressive BP control (<130/80 mmHg), + SGLT2 inhibitor (Dapagliflozin - now evidence-based for HFpEF too).

Blood Pressure Target

  • Target BP <130/80 mmHg (ACC/AHA 2017 guidelines for HTN + HF)
  • Avoid over-diuresis / hypotension which worsens renal perfusion

Monitoring

  • Daily weight (flag if >1.5-2 kg increase over 2 days - adjust diuretic)
  • Daily urine output
  • Serum creatinine + electrolytes (K+) within 1-2 weeks of starting/escalating diuretic or ACEi
  • Repeat echo at 3-6 months to assess LV remodeling response

NYHA Classification (for prognosis and management stratification)

ClassDescription
INo symptoms with ordinary activity
IISlight limitation - comfortable at rest
IIIMarked limitation - comfortable only at rest
IVUnable to carry out any activity without discomfort; symptoms at rest
Assess this patient's class to guide intensity of therapy.

Key Points Summary

  • A 60-year-old hypertensive woman with dyspnea + pedal edema = heart failure until proven otherwise
  • Distinguish HFpEF vs HFrEF with echocardiography - this guides long-term treatment
  • BNP/NT-proBNP and echo are the most important investigations
  • Acute management: sit up + oxygen + IV furosemide
  • Look for and treat any precipitating factor (ACS, arrhythmia, infection, medication non-compliance, dietary indiscretion - high salt intake)
  • Long-term: 4-drug GDMT (ACEi/ARNI + beta-blocker + MRA + SGLT2i) for HFrEF; aggressive BP control + diuretics + SGLT2i for HFpEF
Sources: Goldman-Cecil Medicine (9780323930345), Fuster and Hurst's The Heart 15th Ed. (9781264257560), Tintinalli's Emergency Medicine (9781260019933). Dosing tables from Goldman-Cecil Medicine, p. 3077-3083.
This is a shared conversation. Sign in to Orris to start your own chat.